XVIR THERAPEUTICS
Xvir Therapeutics GmbH was founded in 2004 and is focusing on the clinical development of novel cancer therapies for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors Such cancer therapies are based on the use of oncolytic adenoviruses restoring drug sensitivity and radiation-sensitivity, respectively, of the tumors. Experimental evidence for the efficacy of Xvir’s therapeutic approach has been provided in several animal studies. Xvir’s therapeutic approach is covered by proprietary patents and patent applications, respectively.
XVIR THERAPEUTICS
Industry:
Biotechnology Health Care Hospital
Founded:
2004-01-01
Address:
München, Bayern, Germany
Country:
Germany
Website Url:
http://www.xvir.com
Status:
Active
Contact:
+4908999317446
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt WordPress Apache Wordpress Plugins ReCAPTCHA ReCAPTCHA V2
Similar Organizations
AAPlasma
AAPlasma focus is engineering and development of cold plasma components for your industrial system.
Biomedical Catalyst Fund
Biomedical Catalyst Fund invests in the pre-clinical development and early clinical testing of novel therapeutics.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Official Site Inspections
http://www.xvir.com
- Host name: hp.wam24.com
- IP address: 195.28.12.36
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Xvir Therapeutics"
Xvir Therapeutics - Crunchbase Company Profile
Xvir Therapeutics GmbH was founded in 2004 and is focusing on the clinical development of novel cancer therapies for the treatment of various solid …See details»
Exavir Therapeutics Receives $3M Award from NIH / NIAID to
Aug 22, 2023 “This award speaks to XVIR-110’s transformative potential, but also the importance of American agencies and public-private partnerships in improving population …See details»
Exavir Therapeutics Receives $3M Award from NIH / …
Aug 22, 2023 XVIR-110 is an ultra-long-acting HIV integrase inhibitor with a preclinical profile that suggests best-in-class potential for HIV pre-exposure prophylaxis (PrEP), and for HIV treatment as the ...See details»
Exavir Therapeutics Receives $3M Award from NIH / NIAID to …
Aug 22, 2023 “This award speaks to XVIR-110’s transformative potential, but also the importance of American agencies and public-private partnerships in improving population …See details»
Exavir Therapeutics announces the publication of preclinical data …
Jun 8, 2021 Exavir Therapeutics, a company dedicated to transforming the lives of patients living with or at risk for acquiring HIV, announced today the publication of preclinical data for XVIR …See details»
XVIR-110 - Drug Targets, Indications, Patents - Synapse - Patsnap
XVIR-110: a HIV-1 integrase inhibitors Drug, Initially developed by Exavir Therapeutics, Now, its global highest R&D status is Preclinical, Mechanism: HIV-1 integrase inhibitors(HIV integrase …See details»
Exavir Therapeutics announces preclinical data - GlobeNewswire
Nov 10, 2021 Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir...See details»
Xvir Therapeutics - VentureRadar
Similar Companies: Nammi Therapeutics USA Privately Held Nammi Therapeutics, Inc. is an immunotherapy company developing first in class products for the treatment of cancer. …See details»
Exavir Therapeutics announces the publication of preclinical data …
Jun 8, 2021 With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in …See details»
Exavir Therapeutics announces publication of preclinical data for …
Sep 16, 2021 Exavir Therapeutics, a company dedicated to transforming the lives of patients living with or at risk for acquiring HIV and other viral infections, announced today the …See details»
NIAID grant supports development of ultra-long …
Aug 23, 2023 NIAID grant supports development of ultra-long-acting HIV integrase inhibitor XVIR-110. Aug. 23, 2023. No Comments. Exavir Therapeutics Inc. has received a US$3 million award from the National Institute of Allergy …See details»
Exavir Therapeutics announces preclinical data demonstrating …
Nov 10, 2021 Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles …See details»
Exavir Therapeutics announces publication of preclinical
Sep 16, 2021 As discussed in the publication, a single injection of XVIR-210, Exavir’s proprietary nano-formulated tenofovir prodrug, provided therapeutic exposures of tenofovir to rats for over …See details»
XVir: A Transformer-Based Architecture for Identifying Viral
Aug 29, 2023 In particular, XVir is trained on genomic sequencing reads from viral and human genomes and may be used with tumor sequence information to find evidence of viral DNA in …See details»
XVir: A Transformer-Based Architecture for Identifying Viral Reads …
Aug 29, 2023 In particular, XVir is trained on genomic sequencing reads from viral and human genomes and may be used with tumor sequence information to find evidence of viral DNA in …See details»
Meet XVir: A Promising Transformer-based Approach to Spot Viral …
Sep 8, 2023 XVir is an effort to use deep learning methods and transformers to identify oncogenic viral reads. It is more compact and takes up much less space than the DeepViFi …See details»
Exavir Therapeutics announces the publication of - GlobeNewswire
Jun 8, 2021 With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in …See details»
XVir: A Transformer-Based Architecture for Identifying Viral Reads …
Challenging. In this paper, we introduce XVir, a data pipeline that relies on a transformer-based deep learn-ing architecture to reliably identify viral DNA present in human tumors. In particular, …See details»
[2308.14769] XVir: A Transformer-Based Architecture for …
Aug 28, 2023 In particular, XVir is trained on genomic sequencing reads from viral and human genomes and may be used with tumor sequence information to find evidence of viral DNA in …See details»
Papers with Code - XVir: A Transformer-Based Architecture for ...
Aug 28, 2023 In this paper, we introduce XVir, a data pipeline that relies on a transformer-based deep learning architecture to reliably identify viral DNA present in human tumors. In particular, …See details»